Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) (NCT06919003)
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (RTB-021)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but does not contain any active drug. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Neither you or the study doctor can choose or know which group is assigned. The primary objective is to test whether intrarenal artery C1 esterase inhibitor (C1INH) injection into the donor kidney prior to transplantation improves kidney function in recipients of high risk, deceased donor kidney transplants as measured by 12-month Estimated Glomerular Filtration Rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI)
Who can join: Review the eligibility criteria below.
Location: Cedars Sinai Medical Center — Los Angeles, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Cedars Sinai Medical Center — Los Angeles, California
- Northwestern Memorial Hospital — Chicago, Illinois
- Kansas University Medical Center — Kansas City, Kansas
- Montefiore Medical Center — The Bronx, New York
📞 Contact the Study Coordinator
Phone: (424) 315-1316
Email: tillie.morrisette@cshs.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant
- Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study — Pittsburgh, Pennsylvania
- Pro-active Genetic Testing in Kidney Transplant Patients — Scottsdale, Arizona
- Dapagliflozin in Living-Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Phenotype Guided Vasoactive Medication During Kidney Transplantation — Los Angeles, California
- GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial — Livingston, New Jersey
- Letermovir for R+ Study — Madison, Wisconsin
Explore by condition: All Kidney Transplant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.